Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 434-441

  Stauffer, Virginia L ^a   Millen, Brian A ^a   Andersen, Scott ^a   Kinon, Bruce J ^a   LaGrandeur, Lisa ^a   Lindenmayer, J P ^b   Gomez, Juan Carlos ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Adjunctive therapy; Negative symptoms; Pomaglumetad methionil; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; QUETIAPINE; RISPERIDONE;

ABDOMINAL DISCOMFORT; ADJUVANT THERAPY; ADULT; AGED; AKATHISIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL EFFECTIVENESS; COGNITION; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PAIN; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SCORING SYSTEM; SCREENING TEST; SEIZURE; SIDE EFFECT; SOMNOLENCE; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; VULVOVAGINAL DISEASE; WEIGHT GAIN; XEROSTOMIA;

ADJUNCTIVE THERAPY; NEGATIVE SYMPTOMS; POMAGLUMETAD METHIONIL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AMINO ACIDS; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84886304673     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.020     Document Type: Article

References (26)

1. Adams D.H., Kinon B.J., Baygani S., Millen B.A., Velona I., Kollack-Walker S., Walling D.P. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 2013, 13:143.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders fourth edition 2000, text revision ed, American Psychiatric Association, Washington, DC.
3. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164:1593-1602.
4. Conn P.J., Tamminga C., Schoepp D.D., Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv. 2008, 8:99-107.
5. Coyle J.T., Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl.) 2004, 174:32-38.
6. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
7. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 2001, 158:1367-1377.
8. Goff D.C., Keefe R., Citrome L., Davy K., Krystal J.H., Large C., Thompson T.R., Volavka J., Webster E.L. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J. Clin. Psychopharmacol. 2007, 27:582-589.
9. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, U.S. Department of Health, Education, and Welfare, Rockville, MD.
10. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 2004, 55:165-171.
11. Javitt D.C. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr. Opin. Psychiatry 2006, 19:151-157.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
13. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 2006, 26:453-461.
14. Kinon B., Adams D., Baygani S., Millen B., Velona I., Kollack-Walker S. A long-term, phase 2, safety study of LY2140023 monohydrate vs. atypical antipyschotic standard of care in schizophrenia. Schizophr. Bull. 2011, 37:311.
15. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
16. Kurita M., Holloway T., Garcia-Bea A., Kozlenkov A., Friedman A.K., Moreno J.L., Heshmati M., Golden S.A., Kennedy P.J., Takahashi N., Dietz D.M., Mocci G., Gabilondo A.M., Hanks J., Umali A., Callado L.F., Gallitano A.L., Neve R.L., Shen L., Buxbaum J.D., Han M.H., Nestler E.J., Meana J.J., Russo S.J., Gonzalez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 2012, 15:1245-1254.
17. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2005, 62:1196-1204.
18. Lane H.Y., Lin C.H., Huang Y.J., Liao C.H., Chang Y.C., Tsai G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13:451-460.
19. Laughren T., Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 2006, 32:220-222.
20. Laughren T., Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37:255-256.
21. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58:538-546.
22. McKinzie D.L., Fell M.J., Johnson B.G., Knitowski K.M., Perry K.W., Anderson W.H., Svensson K.A., Monn J.A. Synergistic interactions of the mGlu2/3 receptor agonist LY404039 with antipsychotic agents in behavioral and neurochemical animal models predictive of antipsychotic efficacy. Schizophr. Bull. 2011, 37:110.
23. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
24. Stauffer V.L., Ayan-Oshodi M., Wondmagegnehu E.T., Witcher J., Shen T., Yuen E.S.M., Kryzhanovskaya L., Gertsik L., Wallin D.P. A phase 1B study investigating the potential interaction between LY2140023 and second generation antipsychotics in subjects with schizophrenia or schizoaffective disorder. Schizophr. Res. 2012, 136:S169-S170.
25. Tuominen H.J., Tiihonen J., Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2005, 72:225-234.
26. Umbricht D., Yoo K., Youssef E., Dorflinger E., Martin-Facklam M., Bausch A., Arrowsmith Alberati, Marder S., Santarelli L. Glycine transporter type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schizophr. Bull. 2011, 37:324-325.